Aclaris Therapeutics (ACRS) Competitors $2.24 -0.07 (-2.81%) Closing price 03:59 PM EasternExtended Trading$2.24 0.00 (-0.22%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACRS vs. ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, and PGENShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. AnaptysBio Kura Oncology CorMedix Arbutus Biopharma Pharming Group Immatics ORIC Pharmaceuticals Rapport Therapeutics Septerna Precigen Aclaris Therapeutics (NASDAQ:ACRS) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do analysts rate ACRS or ANAB? Aclaris Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 383.52%. AnaptysBio has a consensus target price of $36.20, suggesting a potential upside of 98.76%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclaris Therapeutics is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29AnaptysBio 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.73 Do insiders and institutionals have more ownership in ACRS or ANAB? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by insiders. Comparatively, 33.7% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ACRS or ANAB? Aclaris Therapeutics received 13 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 66.49% of users gave Aclaris Therapeutics an outperform vote while only 66.19% of users gave AnaptysBio an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38566.49% Underperform Votes19433.51% AnaptysBioOutperform Votes37266.19% Underperform Votes19033.81% Does the media refer more to ACRS or ANAB? In the previous week, AnaptysBio had 8 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 11 mentions for AnaptysBio and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.73 beat AnaptysBio's score of 0.25 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ACRS or ANAB more profitable? Aclaris Therapeutics has a net margin of -136.65% compared to AnaptysBio's net margin of -289.75%. Aclaris Therapeutics' return on equity of -40.26% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% AnaptysBio -289.75%-287.94%-37.25% Which has preferable valuation and earnings, ACRS or ANAB? Aclaris Therapeutics has higher revenue and earnings than AnaptysBio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$31.25M5.20-$88.48M-$0.52-4.38AnaptysBio$17.16M32.30-$163.62M-$6.08-3.00 SummaryAclaris Therapeutics beats AnaptysBio on 13 of the 18 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.50M$7.05B$5.81B$9.13BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-4.385.9925.9319.18Price / Sales5.20324.61463.3381.20Price / CashN/A67.8344.0437.47Price / Book1.026.827.714.77Net Income-$88.48M$138.11M$3.18B$245.80M7 Day Performance-2.36%-0.60%-0.52%-0.80%1 Month Performance-12.50%-0.08%1.71%-0.44%1 Year Performance89.58%-2.10%18.52%16.44% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.454 of 5 stars$2.25-2.8%$11.00+390.0%+90.9%$160.36M$31.25M-4.32100Upcoming EarningsGap UpANABAnaptysBio3.7835 of 5 stars$21.22+10.0%$37.45+76.5%-20.8%$645.73M$17.16M-3.49100High Trading VolumeKURAKura Oncology4.4084 of 5 stars$8.28flat$27.13+227.6%-59.8%$643.85MN/A-3.51130Positive NewsCRMDCorMedix1.2288 of 5 stars$10.48+0.4%$15.67+49.5%+229.3%$635.93M$60,000.00-12.9430Positive NewsABUSArbutus Biopharma1.8146 of 5 stars$3.29-0.3%$5.50+67.2%+19.4%$623.42M$18.14M-7.6590PHARPharming Group2.922 of 5 stars$9.13+3.2%$27.00+195.7%-18.7%$621.19M$285.75M-35.12280Positive NewsGap UpIMTXImmatics1.6278 of 5 stars$5.05-0.8%$16.67+230.0%-59.5%$602.77M$58.44M-7.65260ORICORIC Pharmaceuticals4.5416 of 5 stars$8.36+1.1%$18.71+123.9%-28.7%$589.97MN/A-4.6480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRAPPRapport Therapeutics1.6498 of 5 stars$15.90+0.8%$35.00+120.1%N/A$581.62MN/A0.00N/ASEPNSepternaN/A$12.96+12.2%$43.67+236.9%N/A$575.42MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpPGENPrecigen3.9611 of 5 stars$1.96-1.0%$7.00+257.1%+38.7%$574.03M$6.22M-3.56190 Related Companies and Tools Related Companies AnaptysBio Competitors Kura Oncology Competitors CorMedix Competitors Arbutus Biopharma Competitors Pharming Group Competitors Immatics Competitors ORIC Pharmaceuticals Competitors Rapport Therapeutics Competitors Septerna Competitors Precigen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts